Trunome - Pancreas Care
Trunome Pancreas Care test uses cutting-edge technology to detect the risk of transplant rejection through a simple blood sample. Early identification of rejection can help prevent the loss of a transplanted pancreas and aid in the development of a treatment plan to protect the donated organ.
Trunome’s Pancreas Care test provides a non-invasive way to evaluate the risk of transplant rejection by analyzing a simple blood sample. Early detection of transplant rejection is critical as it can prevent transplant failure, enhance patient outcomes, and eliminate the need for additional transplants.
Without effective tests and treatment, many transplanted organs, including pancreases, can fail soon after the transplantation. Early detection and intervention can improve patient life and reduce the need to go through the lengthy waitlist process again.
Trunome Pancreas Care test is a vital tool in ensuring the long-term success of pancreas transplants by providing regular, non-invasive monitoring through easy blood tests. The blood test detects the presence of antibodies or other markers indicating rejection or injury, allowing healthcare providers to take early action to protect the transplanted pancreas and improve patient outcomes.
The benefits of Trunome’s test, such as its ease of use and the ability to provide repeated sampling for longitudinal analysis, make it essential in safeguarding the patient’s health and enhancing the overall quality of their life after transplantation.
Trunome is a non-invasive method, with a simple blood draw from the post-transplant patient. The collected blood is then analyzed to measure the amount of donor DNA from the transplanted kidney in the patient’s blood.
This measurement can help assess all types of organ rejection more precisely than standard assessment tools that are currently available.
